I’ve never seen a duller drawer full of knives t

I’ve never seen a duller drawer full of knives than you three. Ray, BNP? NanoLogix stayed it did not offer specificity in identifying growth so it wasn’t going anywhere. The N-Assay looks to be brilliant but tests apparently demonstrated that a pretest would assist in marketing so they’re seeking development funding. That makes sense, you could sell pretest/N-Assays in perhaps a 3 or 4:1 ratio and have a marketable cheaper yes/no presence pretest to use with an expensive severity/antibiotic selectivity test within minutes of pretest positive results. As for FlatPacks, how many countries have interest? Doesn’t it take interest to equal money? I’m pleased with the update and now want to see an agreement come to buy or license the patent(s) or even sell the products for NanoLogix. As for costs of $30,000 how much product has to be sold to have that amount of available cash? The majority of the patents were granted late last year, an annuity in case you don’t get it, must be paid each year. I’ll believe that the first year of expenditure including the grant fees for all of those patents must be heavy and they’ll deal with it from sales of some or all of the international patents or even from revenues and sales in the future. Perhaps it’s one of those “wait and see” issues for those companies that are interested, meaning why pay for some small company’s IP if it could simply be available to the public domain if the annuities aren’t paid. Then it comes down to who’s the most efficient producer.

The sky isn’t falling

Scott